BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9275325)

  • 1. Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level.
    Guo R; Thormann W; Lauterberg B
    Chin Med J (Engl); 1996 Dec; 109(12):933-6. PubMed ID: 9275325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between metabolic phenotype of N-acetylation and bladder cancer.
    Cui X; Guo R; Xu Z; Wang B; Li C
    Chin Med J (Engl); 2000 Apr; 113(4):303-5. PubMed ID: 11775223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors.
    Bluhm RE; Adedoyin A; McCarver DG; Branch RA
    Clin Pharmacol Ther; 1999 Jun; 65(6):598-605. PubMed ID: 10391665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylation phenotypes and biological variation in a French Caucasian population.
    Pontes ZB; Vincent-Viry M; Gueguen R; Galteau MM; Siest G
    Eur J Clin Chem Clin Biochem; 1993 Feb; 31(2):59-68. PubMed ID: 8467011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probe.
    William BM; Abdel-tawab AM; Hassan EA; Mohamed OF
    Pol J Pharmacol; 2004; 56(4):445-9. PubMed ID: 15520499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs.
    Palamanda JR; Hickman D; Ward A; Sim E; Romkes-Sparks M; Unadkat JD
    Drug Metab Dispos; 1995 Apr; 23(4):473-7. PubMed ID: 7600914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283).
    Winter HR; Trapnell CB; Slattery JT; Jacobson M; Greenspan DL; Hooton TM; Unadkat JD
    Clin Pharmacol Ther; 2004 Dec; 76(6):579-87. PubMed ID: 15592329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeine as a potential indicator for acetylator status.
    Rankin RB; Hudson SA; Fell AF
    J Clin Pharm Ther; 1987 Feb; 12(1):47-51. PubMed ID: 3449563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylation polymorphism of caffeine in a Japanese population.
    Hashiguchi M; Ebihara A
    Clin Pharmacol Ther; 1992 Sep; 52(3):274-6. PubMed ID: 1526084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylation of dapsone by human whole blood.
    Irshaid YM; al-Hadidi HF; Abuirjeie MA; Rawashdeh NM; Gharaibeh NS
    Int J Clin Pharmacol Ther Toxicol; 1993 Jan; 31(1):18-22. PubMed ID: 8444513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of dapsone and acetylated dapsone in serum and saliva.
    Lammintausta K; Kangas L; Lammintausta R
    Int J Clin Pharmacol Biopharm; 1979 Apr; 17(4):159-63. PubMed ID: 447435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylator phenotype in Iraqi patients with atopic dermatitis.
    Najim RA; Al-Waiz MM; Al-Razzuqi RA
    Dermatol Online J; 2006 Dec; 12(7):1. PubMed ID: 17459287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylator phenotype in Iraqi patients with systemic lupus erythematosus.
    Najim RA; Farid YY; Samad TA; Shihab SA
    East Mediterr Health J; 2005; 11(5-6):1003-8. PubMed ID: 16761671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminopyrine metabolism in man: the acetylation of aminoantipyrine cosegregates with acetylation of caffeine.
    Agúndez JA; Carrillo JA; Martínez C; Benítez J
    Ther Drug Monit; 1995 Feb; 17(1):1-5. PubMed ID: 7725368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-acetylation polymorphism of dapsone in a Japanese population.
    Horai Y; Ishizaki T
    Br J Clin Pharmacol; 1988 Apr; 25(4):487-94. PubMed ID: 3382590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-adipose administration of monoacetyldapsone to healthy volunteers.
    Pieters FA; Zuidema J
    Int J Lepr Other Mycobact Dis; 1986 Dec; 54(4):510-6. PubMed ID: 3819527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylator phenotype and the effect of dapsone in rheumatoid arthritis.
    Crook PR; Hortas C; Roberts EJ; Swinson DR; Mucklow JC; Shadforth MF
    J Rheumatol; 1983 Oct; 10(5):805-8. PubMed ID: 6644705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-acetylation phenotyping using dapsone in a Jordanian population.
    Irshaid YM; al-Hadidi HF; Abuirjeie MA; Rawashdeh NM
    Br J Clin Pharmacol; 1991 Sep; 32(3):289-93. PubMed ID: 1777365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-reactivity in HIV-infected patients switched from trimethoprim-sulfamethoxazole to dapsone.
    Holtzer CD; Flaherty JF; Coleman RL
    Pharmacotherapy; 1998; 18(4):831-5. PubMed ID: 9692656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.